PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE) of Castration Resistant Prostate Cancer (CRPC) Patients Treated with Abiraterone Acetate

ANALYTE_TYPE - Analyte type (phv00265255.v2.p1)
BODY_SITE - Body site where sample was collected (phv00265254.v2.p1)
BODY_SITE_CATEGORY - Body site where sample was collected (phv00265264.v2.p1)
composite_progression - Composite endpoint for progression after 12 weeks of abiraterone acetate chemotherapy (12-14 weeks or earlier if progression is suspected). The progression is judged based on PSA levels, radiography estimate progression, and symptoms assessments. (phv00265251.v1.p1)
CONSENT - Consent group as determined by DAC (phv00265239.v1.p1)
HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00265262.v2.p1)
IS_TUMOR - Tumor status (phv00265256.v2.p1)
PRIMARY_METASTATIC_TUMOR - Primary metastatic tumor (phv00265257.v2.p1)
PRIMARY_TUMOR_LOCATION - Primary tumor location (phv00265258.v2.p1)
SAMPLE_ID - De-identified sample ID (phv00265253.v2.p1)
SAMPLE_ID - Sample ID (phv00265244.v2.p1)
SAMPLE_SOURCE - Source repository where samples originate (phv00265245.v2.p1)
SAMPLE_USE - Sample Use (phv00265247.v2.p1)
SEQUENCING_CENTER - Name of the center which conducted sequencing (phv00265263.v2.p1)
SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00265246.v2.p1)
Stage - Stage (phv00265259.v2.p1)
SUBJECT_ID - Subject ID (phv00265243.v2.p1)
SUBJECT_ID - De-identified subject ID (phv00265248.v1.p1)
SUBJECT_ID - Subject ID (phv00265238.v1.p1)
TREATMENT_POST_VISIT - Treatment post visit (phv00265261.v2.p1)
TUMOR_TREATMENT - Tumor treatment (phv00265260.v2.p1)